LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

LLY

701.97

+2.52%↑

JNJ

176.85

+1.02%↑

ABBV

206.8

+1%↑

NVS

123.84

+1.28%↑

AZN

79.17

+0.81%↑

Начало・Списък с акции・Amicus Therapeutics Inc

Amicus Therapeutics Inc

Затворен

СекторЗдравеопазване

7.41 3.64

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

7.31

Максимум

7.41

Ключови измерители
By Trading Economics
Приходи	-2.7M -24M
Продажби	29M 155M
Марж на печалбата	-15.787
Служители	499
EBITDA	-65M -70M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+99.86% upside

Пазарни показатели
By TradingEconomics
Пазарна капитализация	167M 2.1B
Предишно отваряне	3.77
Предишно затваряне	7.41

Настроения в новините

By Acuity

50%

157 / 374 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

5.925 / 7.38 Подкрепа & съпротива

Amicus Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

15.08.2025 г., 16:11 ч. UTC

Значими двигатели на пазара

Health Insurers Climb as Berkshire Hathaway Takes UnitedHealth Stake

15.08.2025 г., 22:22 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

15.08.2025 г., 22:22 ч. UTC

Пазарно говорене

Target Is Falling Behind Its Peers -- Market Talk

15.08.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.08.2025 г., 20:33 ч. UTC

Пазарно говорене

U.S. Treasury Yields Close the Week Little Changed -- Market Talk

15.08.2025 г., 20:25 ч. UTC

Печалби

Придобивния, сливания и поглъщания

This Meatpacker Stock Is a Quality Buy at a Discount Price -- Barrons.com

15.08.2025 г., 20:24 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15.08.2025 г., 20:18 ч. UTC

Печалби

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15.08.2025 г., 19:14 ч. UTC

Пазарно говорене

U.S. Natural Gas Settles Higher, But Down on Week -- Market Talk

15.08.2025 г., 19:12 ч. UTC

Пазарно говорене

Oil Futures Settle Lower Ahead of U.S.-Russia Summit -- Market Talk

15.08.2025 г., 18:32 ч. UTC

Пазарно говорене

Coffee Futures Surge on New Brazilian Frost -- Market Talk

15.08.2025 г., 17:33 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Increases By 1 to 412 -- Market Talk

15.08.2025 г., 17:23 ч. UTC

Пазарно говорене

Печалби

Deere's Earnings Appear to Be Troughing -- Market Talk

15.08.2025 г., 16:27 ч. UTC

Печалби

Tariffs Have Rocked e.l.f. Beauty Shares. Why the Fundamentals Still Look Alluring. -- Barrons.com

15.08.2025 г., 16:20 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

15.08.2025 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

15.08.2025 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

15.08.2025 г., 16:05 ч. UTC

Придобивния, сливания и поглъщания

Intel's Move Toward Nationalization Won't Work -- at Least for the Long Haul -- Heard on the Street -- WSJ

15.08.2025 г., 15:52 ч. UTC

Придобивния, сливания и поглъщания

What Applied Materials' Poor Outlook Means for Chip Stocks -- Barrons.com

15.08.2025 г., 15:36 ч. UTC

Пазарно говорене

Base Metal Prices Mixed; Copper Gains as Focus Shifts to Fundamentals -- Market Talk

15.08.2025 г., 15:29 ч. UTC

Печалби

Deere's Earnings Brought a Surprise. It Wasn't the Usual Kind. -- Barrons.com

15.08.2025 г., 15:29 ч. UTC

Придобивния, сливания и поглъщания

Nucor Stock Gets a Boost From Buffett. Berkshire's Last Steel Buy Didn't Go So Well. -- Barrons.com

15.08.2025 г., 15:28 ч. UTC

Печалби

JD.com Stock Rises After Earnings Beat. Why Investors Are Relieved. -- Barrons.com

15.08.2025 г., 15:24 ч. UTC

Пазарно говорене

Gold Futures Tick Higher But Remain Broadly Rangebound -- Market Talk

15.08.2025 г., 15:08 ч. UTC

Пазарно говорене

Applied Materials Is Losing Share in Chips Business -- Market Talk

15.08.2025 г., 14:38 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Own 19.9% of Surge Copper Shares

15.08.2025 г., 14:37 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares for C$4.51M

15.08.2025 г., 14:37 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Buy 25.8 Million Surge Copper Shares at C$0.175 Each

15.08.2025 г., 14:36 ч. UTC

Придобивния, сливания и поглъщания

African Rainbow Minerals to Acquire Shares of Surge Copper Corp.

15.08.2025 г., 14:33 ч. UTC

Придобивния, сливания и поглъщания

A Trump Intel Stake Could Make National Security the New 'Too Big to Fail' -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Amicus Therapeutics Inc Прогноза

Ценова цел

By TipRanks

99.86% нагоре

12-месечна прогноза

Среден 14.79 USD 99.86%

Висок 20 USD

Нисък 6.5 USD

Според 8 анализатори от Wall Street, предложили 12-месечна ценова цел за Amicus Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

8 ratings

Купи

Задържане

Продай

Според 8 анализатори, дали борсови рейтинги на Amicus Therapeutics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.925 / 7.38Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

157 / 374 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Amicus Therapeutics Inc

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.